


英文名 | PCLX-001 | ||
级别 | For Signal Pathway Regulation | 相关类别 | 其他 |
储存 | 冷冻(-20℃) 避光 | 分子量 | 537.51 |
靶点 | Others | ||
编 号 | 包装 | 库存 | 目录价(¥) | 您的价格(¥) | 数 量 |
A417889-0001 | 1 MG | 咨询 |
![]() |
![]() |
![]() |
A417889-0005 | 5 MG | 咨询 |
![]() |
![]() |
![]() |
A417889-0010 | 10 MG | 咨询 |
![]() |
![]() |
![]() |
A417889-0025 | 25 MG | 咨询 |
![]() |
![]() |
![]() |
A417889-0050 | 50 MG | 咨询 |
![]() |
![]() |
![]() |
A417889-0100 | 100 MG | 咨询 |
![]() |
![]() |
![]() |
概述
PCLX-001 is a small-molecule compound that acts as an orally active inhibitor of N-myristoyltransferase (NMT), specifically targeting NMT1 and NMT2 with IC50 values of 5 nM and 8 nM, respectively. This compound demonstrates anti-tumor effects and effectively inhibits the early signaling of B-cell receptor (BCR). Consequently, PCLX-001 is a valuable tool for researching B-cell malignancies [1] [2].
属性
保存温度&条件 | 低温,避光;粉末:-20°C,2年;在溶剂中:-80°C,1年 |
信号通路 | 其他 |